ETMarkets.com
Walmart Set to Replace AstraZeneca in Nasdaq-100 on January 20
Walmart is preparing to make a significant move on January 20, when it will replace AstraZeneca in the Nasdaq-100 Index. This transition marks Walmart’s shift from the New York Stock Exchange (NYSE) to its main competitor, Nasdaq.
Key Details of the Transition
– Date of Change: January 20
– Company Being Replaced: AstraZeneca, the British pharmaceutical giant
– New Listings: Walmart will be included in the Nasdaq-100 Index, the Nasdaq-100 Equal Weighted Index, and the Nasdaq-100 Ex-Tech Sector Index.
Why Companies Switch Exchanges
Companies often change their listing venues for several reasons, including:
– Alignment with Investor Base: Finding better alignment with an exchange’s investor demographics.
– Access to Technology and Services: Gaining improved technological and support services.
– Cost-Effective Solutions: Reducing expenses related to listing and compliance.
In 2025, several companies that transitioned from the NYSE to the Nasdaq cited the desirability of the Nasdaq-100 Index—comprising the 100 most valuable non-financial companies on the exchange, which include industry leaders like Nvidia and Apple.
As Walmart prepares for this shift, its inclusion in the Nasdaq-100 Index is poised to strengthen its position in the market, reflecting the growing trend of companies seeking opportunities that align with their business strategies.
Conclusion
Walmart’s transition to the Nasdaq-100 on January 20 not only highlights its strategic direction but also underscores the competitive landscape between major stock exchanges. This move is indicative of Walmart’s continuous pursuit of alignment with investor sentiments and technological advantages, promising potential benefits for both the company and its stakeholders.